Tagged with Saudi Arabia

Saudi Arabia Amgen’s Middle East and Africa General Manager Mohamed Nasser discusses the company’s approach to the region; the opportunities in the Saudi market, given its improved regulatory environment; and the disadvantages of its reference pricing system. In addition, Nasser explains Amgen’s approach to Saudization and the company’s place within Saudi Arabia’s…

Saudi Arabia Georg Schroeckenfuchs, Novartis’ president MEA and head of its Gulf and Saudi Country Group, explains how the company’s objectives are aligned with Saudi Arabia’s Vision 2030, the progress made towards the nationalization of its Saudi workforce, the potential impact of changes in the tender process, and why Novartis is uniquely…

Saudi Arabia Bristol Myers Squibb’s General Manager for the Middle East and Africa (MEA) Oscar Delgado outlines the company’s pandemic journey, the big changes transforming the Saudi market, the challenges on regulatory data protection, and the opportunities to make Saudi Arabia a leader in clinical trials and innovation within the region.  …

Saudi Arabia Historically dependent on oil, Saudi Arabia, like most countries in the Arabian Peninsula, is now investing a large chunk of the sizeable resources obtained from fossil fuels in diversifying its economy. Pharmaceuticals, as one of the strategic sectors in the country’s diversification strategy, has reaped the benefits and the Saudi…

Saudi Arabia Haitham Habashi, general manager for Merck Saudi Arabia, outlines his affiliate’s approach to the big reforms shaping the country’s healthcare system, discusses the new public procurement process, and explains why Vision 2030 means transformative opportunities for Saudis, women, and health. Moreover, he highlights Merck’s manufacturing in Saudi Arabia and its…

MEA The latest Middle East and North Africa (MENA) pharma, including Egypt’s opening of the largest “pharmaceutical city” in the Middle East and Abu Dhabi’s quest to become a pharma hub with the goal of distributing billions of vaccines.   Turkish Koçak Farma’s COVID-19 vaccine has begun Phase I clinical trials…

Saudi Arabia When it comes to knowledge of the Middle East and Africa region’s pharmaceutical industry, few executives have the experience of Dr Alaa Gamal. After more than 27 years of experience with Pfizer and GSK, he discusses how companies are helping governments transform the regulatory hurdles, the increasing talent pool available…

Saudi Arabia The Pharmaceutical Research and Manufacturers of America (PhRMA) represents many of the world’s leading innovative biopharmaceutical research companies. Its executive director for the Middle East and Africa, Samir Khalil, discusses the need for a value-based pricing system in Saudi Arabia, the country’s successful COVID-19 response and how the Vision 2030…

Saudi Arabia Rubens Hannun, president of the Arab Brazilian Chamber of Commerce, discusses the commercial relationship between Brazil and Saudi Arabia, which now reaches over US USD three billion between imports and exports, the role of pharmaceuticals, the opportunities in halal products and their efforts to inform the Arab and Brazilian business…

Saudi Arabia Bandar Reda outlines the evolution of the trading relationship between the UK and the Arab world, the role of the Arab British Chamber of Commerce in facilitating stronger ties, and why initiatives like Saudi Arabia’s ‘Vision 2030’ provide abundant opportunities for healthcare and life sciences investment.   With a clear…

Saudi Arabia In a recent conversation with PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA) outlined the organisation’s strategic priorities. As part of the Authority’s 2018-2022 strategic plan, it has set out a number of goals, ranging from setting clearer objectives to strengthening its capabilities,…

Saudi Arabia Speaking exclusively to PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA), outlines the SFDA’s key priorities under its current strategic plan. He also touches on why domestic pharma and medtech manufacturing is important to the SFDA, pricing issues for innovative new therapies, and…